26–28 October 2026 | Addis Ababa, Ethiopia
The Medicines Patent Pool (MPP) is pleased to participate in the African Healthcare Manufacturing Trade Exhibition and Conference (AHMTEC) 2026, taking place from 26 to 28 October in Addis Ababa, Ethiopia.
AHMTEC brings together pharmaceutical manufacturers, policymakers, industry leaders and development partners to explore opportunities for strengthening local manufacturing capacity and building a more sustainable and resilient healthcare manufacturing ecosystem in Africa.
At AHMTEC 2026, MPP will highlight how voluntary licensing, technology transfer and strategic partnerships can support regional pharmaceutical manufacturing, strengthen supply chains and expand access to quality-assured medicines in low- and middle-income countries.
Title: Partner to Perform – Key contracting levers that manufacturers must consider
Date & time: 12:25-13:15 EAT, 27 October 2026
Session overview
Tiwadayo Braimoh, Senior Manager, Policy, Strategy and Market Access at the Medicines Patent Pool (MPP), will speak at AHMTEC 2026 during the session “Partner to Perform.”
The session will explore how strategic partnerships can create lasting value for all parties, drawing on practical partnership models across pharmaceuticals, vaccines, diagnostics and medical devices.
Drawing on MPP’s experience in voluntary licensing and collaboration with manufacturers, Tiwa will contribute perspectives on how effective partnerships can support sustainable local manufacturing, expand access to essential health products and strengthen Africa’s healthcare manufacturing ecosystem.
Throughout the conference, MPP welcomed partners and participants at Booth S1 in the exhibition area.
Our team looks forward to discussing how voluntary licensing, technology transfer and partnerships can help support sustainable manufacturing and improve access to essential medicines across the region.
We invite all AHMTEC participants to share their perspectives through an interactive word cloud at the MPP booth.
Simply scan the QR code displayed at our booth, submit your answer and watch the word cloud evolve in real time as more participants contribute.
Your insights will help spark conversations about the priorities, partnerships and actions needed to strengthen pharmaceutical manufacturing across Africa.
Contribute to the live word cloud
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.